OncoMatch/Clinical Trials/NCT06889493
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Is NCT06889493 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Seneca Valley Virus-001 (SVV-001) and Nivolumab for neuroendocrine carcinoma.
Treatment: Seneca Valley Virus-001 (SVV-001) · Nivolumab · Ipilimumab — The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Required: Stage ADVANCED METASTATIC
Metastatic disease required
Grade: 3
advanced metastatic disease that has progressed on at least one line of available therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any available therapy
disease that has progressed on at least one line of available therapy
Cannot have received: cytotoxic chemotherapy
Has had cytotoxic chemotherapy or radiation therapy within 3 weeks
Cannot have received: radiation therapy
Has had cytotoxic chemotherapy or radiation therapy within 3 weeks
Cannot have received: biologic therapy
less than 5 half-lives or 6 weeks, whichever is shorter, from prior biologic therapies, prior to the first dose of SVV-001
Lab requirements
Blood counts
ANC ≥1500 cells/µL; Platelet count ≥100,000/µL; Hemoglobin ≥9.0 g/dL; INR within institutional normal range; Normal PT and PTT
Kidney function
Creatinine clearance ≥50 mL/minute using Cockcroft Gault equation
Liver function
ALT and AST ≤2.5 × ULN (≤5 × ULN if liver metastases are present); bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis)
Cardiac function
Patients with an ejection fraction (EF) < 50 on a 2D echocardiogram (ECHO) excluded
Adequate hematological, renal, and liver function defined as follows: ... ALT and AST ≤2.5 × ULN (≤5 × ULN if liver metastases are present); bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis); Creatinine clearance ≥50 mL/minute using Cockcroft Gault equation; ANC ≥1500 cells/µL; Platelet count ≥100,000/µL; Hemoglobin ≥9.0 g/dL; INR within institutional normal range; Normal PT and PTT. Patients with an ejection fraction (EF) < 50 on a 2D echocardiogram (ECHO) excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify